Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Dansk
English
Søg efter indhold i Region Hovedstadens forskningsportal
Forside
Hospitaler/Afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Dostarlimab and niraparib in primary advanced ovarian cancer
A-C Hardy-Bessard
, E Pujade-Lauraine
, R G Moore
, F Montestruc
, A Redondo
,
M R Mirza
, D Cibula
, T-E Ciuleanu
, L Gilbert
, R Eitan
, F Zagouri
, S Pignata
, R Glasspool
, J Pfisterer
, R Phaëton
, C K Anderson
, M Rodrigues
, L Gaba
, E Bakirtzi
, J M Fauci
E Kalbacher, F B Musa, S Gorman, L R Duska, L Gladieff, P Braly, F Joly, J Thomes Pepin, I Ray-Coquard, K N Moore
Vis 10 andre
Vis mindre
Afdeling for Kræftbehandling
30
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Dostarlimab and niraparib in primary advanced ovarian cancer'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Primary Ovarian Cancer
100%
Niraparib
100%
Dostarlimab
100%
Platinum-based Chemotherapy
80%
Placebo
60%
Overall Survival
60%
Progression-free Survival
60%
Advanced Ovarian Cancer
60%
Hazard Ratio
40%
95% Confidence Interval
40%
PARP Inhibitors (PARPi)
40%
Newly Diagnosed
20%
Efficacy Analysis
20%
Randomized Double-blind
20%
Intention-to-treat
20%
Safety Profile
20%
Improved Outcomes
20%
Phase II Trial
20%
Bevacizumab
20%
Stage III-IV
20%
2-median
20%
Survival Improvement
20%
ENGOT
20%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
20%
Statistically Significant Difference
20%
Treatment Lines
20%
First-line Platinum-based Chemotherapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Chemotherapy Regimens
100%
Niraparib
100%
Platinum
100%
Placebo
60%
Overall Survival
60%
Progression Free Survival
60%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
40%
Bevacizumab
20%
Immunotherapy
20%
Phase III Trials
20%